内科理论与实践 ›› 2024, Vol. 19 ›› Issue (01): 31-35.doi: 10.16138/j.1673-6087.2024.01.06

• 专家论坛 • 上一篇    下一篇

对耶氏肺孢子菌肺炎患者进行复方磺胺甲噁唑治疗药物监测的重要性研究

方洁a(), 陈超a, 周敏b   

  1. a.上海交通大学医学院附属瑞金医院 药剂科,上海 200025
    b.上海交通大学医学院附属瑞金医院 呼吸与危重症医学科上海交通大学医学院呼吸病研究所,上海 200025
  • 收稿日期:2023-10-26 出版日期:2024-02-29 发布日期:2024-04-28
  • 通讯作者: 方洁 E-mail:fj40517@rjh.com.cn

Importance of drug monitoring for compound sulfamethoxazole therapy in patients with Pneumocystis jiroveci pneumonia

FANG Jiea(), CHEN Chaoa, ZHOU Minb   

  1. a. Department of Pharmacy, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    b. Pulmonary and Critical Care Medicine, Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Received:2023-10-26 Online:2024-02-29 Published:2024-04-28
  • Contact: FANG Jie E-mail:fj40517@rjh.com.cn

摘要:

耶氏肺孢子菌肺炎(Pneumocystis jiroveci pneumonia,PJP)是人类免疫缺陷病毒(human immunodeficiency virus,HIV)患者较为常见和严重的机会性感染之一。随着免疫抑制剂及化疗药物等的使用,目前国内报道PJP多数为非HIV免疫抑制患者。复方磺胺甲噁唑(sulfamethoxazole complex, SMZco)是治疗PJP的一线药物,其药动学存在广泛的个体差异。本文通过引用1例药物监测下SMZco治疗PJP的病例,从SMZco的药代动力学、剂量相关不良反应以及最佳治疗剂量研究等方面进行系统综述,旨在表明对PJP患者进行SMZco治疗药物监测的重要性,通过药物监测以确保患者达到有效治疗浓度,减少不良反应的发生。

关键词: 耶氏肺孢子菌肺炎, 复方磺胺甲噁唑, 治疗药物监测

Abstract:

Pneumocystis jiroveci pneumonia (PJP) is one of the more common and serious opportunistic infections in patients with human immunodeficiency virus (HIV). With the use of immunosuppressants and chemotherapy drugs, most PJP cases reported in China are non-HIV immunosuppressed patients. Compound sulfamethoxazole (SMZco) is the first-line drug for the treatment of PJP, and there are wide individual differences in its pharmacokinetics. Through citing a PJP case treated with SMZco under drug monitoring, a systematic review was conducted from the aspects of SMZco pharmacokinetics, dose-related adverse reactions, and optimal therapeutic dose research. It aims to demonstrate the importance of drug monitoring for sulfamethoxazole therapy, which ensures the drug reaches effective therapeutic concentrations and the occurrence of its’ adverse reactions was reduced.

Key words: Pneumocystis jiroveci pneumonia, Compound sulfamethoxazole, Therapeutic drug monitoring

中图分类号: